R
ecent studies have implicated a role for the NLRP3 inflammasome in atherogenesis in patients at risk for developing cardiovascular disease. The CAN-TOS trial (Canakinumab Antiinflammatory Thrombosis Outcome Study) has shown that in patients with a previous myocardial infarction and evidence of systemic inflammation, antagonism of interleukin (IL)-1β, one of the major products of the inflammasome, reduces coronary heart disease.
1 TET2 mutations that are associated with clonal hematopoiesis and increased cardiovascular disease risk in humans 2 activate the NLRP3 inflammasome in myeloid cells, enhancing IL-1β production, 3 which appears to be key to their proatherogenic effects. 3 Under specific conditions, the NLRP3 inflammasome may thus be activated and contribute to cardiovascular disease. The products of the NLRP3 inflammasome, IL-1β and IL-18, accelerate atherosclerosis in mice, [4] [5] [6] [7] [8] but studies on the role of the NLRP3 inflammasome in atherogenesis have yielded mixed results, with deficiency of Nlrp3 or other inflammasome components either decreasing atherogenesis 4, [9] [10] [11] [12] or showing no effect. 13, 14 The mechanisms and significance of NLRP3 inflammasome activation in atherosclerosis remain poorly understood.
The cholesterol transporters ATP binding cassette A1 and G1 (ABCA1 and ABCG1) mediate cholesterol efflux to apolipoprotein A1 and high-density lipoprotein (HDL), 15 and the capacity of HDL to mediate macrophage cholesterol efflux inversely correlates with cardiovascular disease risk in humans. 16 We recently found that mice with cholesterol accumulation in dendritic cells due to deficiency of ABCA1 and ABCG1 showed NLRP3 inflammasome activation contributing to their autoimmune phenotype, 17 but the mechanisms of inflammasome activation were not determined. While myeloid Abca1/g1 deficiency did not induce autoimmunity, 17 myeloid Abca1/g1 deficiency had been previously shown to increase atherosclerotic lesion area in mice. 15 This led us to investigate the role of the inflammasome in atherogenesis in mice with myeloid Abca1/g1 deficiency.
METHODS
The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure on reasonable request. 
Animals

Caspase1 -/-
11
-/-mice were generated by crossbreeding Abca1 
-/-mice. Abca1 -/-mice were generated as described. 18 All procedures followed were in accordance with the Institutional Animal Care and Use Committee of Columbia University.
Patients
Patients with Tangier disease (TD) and their family members (heterozygous ABCA1 mutation carriers) and age-and sexmatched controls were recruited at the Academic Medical Center, Amsterdam, and at the University of Pennsylvania. 19, 20 Subjects gave informed consent. Studies were approved by the respective institutional review boards. Data transfer was approved by the institutional review board of Columbia University.
Statistics
All data are presented as means±SEM. The t test was used to define differences between 2 data sets. For ≥3 data sets, 1-way ANOVA was used with a Bonferroni multiple comparison posttest. For mortality studies, the log-rank (Mantel-Cox) test was used.
To define differences between (1) age-and sex-matched controls, (2) ABCA1 heterozygous mutation carriers, and (3)
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patients with TD, mixed-effects models with random intercepts were used, taking into account data clustering due to family members. Restricted maximum likelihood estimation and type 3 generalized score statistics were used for testing significance of the factor group, and data were log-transformed to meet model assumptions of normality. Significance levels for pairwise comparisons of estimated marginal means were Bonferroni-corrected to account for multiple testing. An expanded version of the Methods section can be found in the online-only Data Supplement. Figure 1A and 1B). These data were obtained in female mice; male mice showed similar phenotypes (not shown). Myeloid Abca1/g1 deficiency led to caspase-1 cleavage in splenic homogenates, a hallmark of inflammasome activation, with reversal by Nlrp3 deficiency ( Figure 1C and 1D and Figure IC (Figure 2A and 2B We examined the mechanism underlying the effect of the inflammasome on atherogenesis. Myeloid Abca1/ g1 deficiency increased blood monocyte and neutrophil levels by 2-fold ( Figure 
RESULTS
Myeloid
Nlrp3
-/-CD11b + splenocytes ( Figure 1G ). To assess neutrophils, we stained atherosclerotic plaques for Ly6G and myeloperoxidase, which is released on neutrophil activation. 21 Myeloid Abca1/g1 deficiency dramatically increased Ly6G and myeloperoxidase staining in plaques, indicating neutrophil accumulation and activation in cellular areas and necrotic cores. 
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findings showing that neutrophils mainly contribute to early lesion development, 22, 23 and likely explaining the more pronounced effect of inflammasome activation on lesion area at the earlier time point. To assess whether NETosis was due to a cell-intrinsic effect, we isolated neutrophils and studied spontaneous NETosis in cell culture. At 4 hours after isolation, we observed overlap in staining for citrullinated histones with 4ʹ,6-diamidino-2-phenylindole (DAPI) in Ly6G + neutrophils ( Figure VI in -fractions of the aorta (n=3 samples per group with 2 aortas per group pooled) (Figure VIIA through VIIC in the online-only Data Supplement), suggesting that myeloid Abca1/g1 deficiency was not activating the inflammasome directly in plaques.
The genetic evidence (Figure 3) shows for the first time that lesional neutrophil recruitment and NETosis may be promoted downstream of the inflammasome, likely driving early atherogenesis. 24 However, myeloid Abca1/g1 deficiency caused NETosis in atherosclerotic plaques ( Figure 3E through 3G and Figures IV and V in the online-only Data Supplement) by enhancing neutrophil recruitment or activation rather than via cellintrinsic effects in neutrophils.
Patients Who Have TD With ABCA1
Loss of Function Show Markers of Inflammasome Activation
Combined deficiency of Abca1 and Abcg1 represents an extreme model of defective cholesterol efflux. We thus questioned whether deficiency of both cholesterol transporters was required for inflammasome activation. We found that myeloid Abca1 or Abcg1 deficiency alone did not affect plasma IL-18 levels in WTD-fed Ldlr -/-mice ( Figure 4A ). However, whole-body Abca1 deficiency did activate the inflammasome ( Figure 4B through 4D), likely because this causes both low plasma HDL, eliminating the acceptor for macrophage AB-CG1-mediated cholesterol efflux, and myeloid Abca1 (A and B) , and in activated neutrophils using myeloperoxidase (MPO) (C and D), Ly6G + and MPO + percentage of lesion size was quantified (n=5-8 mice per group). E and F, Lesions were also stained for citrullinated histones 2, 8, and 17 (3HCit). To assess NETs, the overlap of Ly6G and 3HCit (E) or MPO and 3HCit (Continued )
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deficiency. Patients with TD are homozygous for an ABCA1 loss-of-function mutation. 25 To assess potential inflammasome activation in TD subjects, we measured plasma IL-1β and IL-18 levels. This showed marked increases in comparison with sex-and age-matched controls 19, 20 and ABCA1 heterozygotes ( Figure 4E and 4F and Table II in the online-only Data Supplement), suggesting that cholesterol efflux pathways also suppress inflammasome activation in humans.
NLRP3 Inflammasome Activation Is Cholesterol Dependent
Myeloid Abca1/g1 deficiency increases cholesterol accumulation in macrophages and monocytes on the chow diet, and more so in Ldlr -/-mice fed WTD. 15 Myeloid Abca1/g1 deficiency also enhanced free and esterified cholesterol accumulation in splenic neutrophils ( Figure 5A ).
Further analysis of splenocytes showed that myeloid Abca1/g1 deficiency induced caspase-1 cleavage in monocytes (CD115 + and Ly6G In addition to the priming signal, inflammasome activation in macrophages requires a second signal, potentially including lysosomal free cholesterol accumulation, cholesterol crystals, mitochondrial reactive oxygen species (ROS), or ATP. 4, 27, 28 Myeloid Abca1/g1 deficiency enhanced free cholesterol accumulation in lysosomes of splenic monocytes/macrophages ( Figure 5G and 5H) and free cholesterol accumulation in neutrophils (Figure 5A) . To assess the presence of cholesterol crystals, we used confocal reflectance microscopy in splenic cell suspensions while keeping the samples at 37°C to avoid cooling, which may result in artefactual formation of crystalline cholesteryl esters. 29 We observed a 37% increase in refractile material in splenic cells of WTD-fed Myl-Abc dko BMT Ldlr -/-mice, perhaps suggesting minor cholesterol microcrystal formation ( Figure 5I and 5J). Free cholesterol accumulation in lysosomes may activate the inflammasome by increasing lysosomal pH, compromising lysosomal function. 30 However, lyso- , and Abca1 -/-mice were fed WTD for 4 weeks, and plasma IL-18 levels (B) and caspase-1 cleavage in total splenocytes (C and D) were assessed. In A and B, each data point represents 1 mouse. D, Controls represent wild-type and Abca1 +/-mice. IL-1β (E) and IL-18 (F) levels were measured in plasma of patients with Tangier disease (TD) carrying a homozygous loss-of-function mutation for ABCA1, and sex-and age-matched heterozygous ABCA1 mutation carriers and controls. Each data point represents 1 patient or control. *P<0.05, **P<0.01, ***P<0.001 by t test (D) or 1-way ANOVA with Bonferroni posttest (A and B) or a mixed-effects model with random intercepts taking into account data clustering because of family members (E and F). ABC indicates ATP binding cassette; BM, bone marrow; het, heterozygous; IL, interleukin; and WTD, Western-type diet.
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tracker and lysosensor stainings were unchanged (Figure 5G , 5H, 5K, and 5L, and Figure IXA and IXB in the online-only Data Supplement), suggesting that the lysosomal pH remained unaffected. We further assessed the contribution of cholesterol accumulation to inflammasome activation by injecting mice with reconstituted HDL (CSL-111), which promotes cholesterol efflux from Abca1/g1-deficient macrophages by passive efflux mechanisms. 15 Reconstituted HDL injections reduced the increase in IL-18 plasma levels in WTD-fed Myl- Monocytes secrete ATP and thus require only a priming signal for inflammasome activation. 27 Myeloid Abca1/ g1 deficiency increased ATP secretion from total splenic monocytes by 2-fold ( Figure 5N) ; however, this was simply proportional to a 2-fold increase in the splenic monocyte population of Myl-Abc dko BMT Ldlr -/-mice in comparison with controls ( Figure IXA and IXI in the online-only Data Supplement). Moreover, myeloid Abca1/ g1 deficiency enhanced the secretion of IL-1β and IL-18 in lipopolysaccharide-treated BM-derived macrophages at the same concentration of ATP as controls ( Figure  IXJ and IXK in the online-only Data Supplement). This result is consistent with increased inflammasome priming in Abca1/g1-deficient macrophages due to an enhanced lipopolysaccharide response. 31 Thus, our findings suggest a major contribution of cellular cholesterol accumulation to inflammasome activation in Myl-Abc dko BMT Ldlr -/-mice, in the absence of overt cholesterol crystal formation, lysosomal dysfunction, or increased ATP production, implicating a novel cholesterol-sensing mechanism that provides a second signal of inflammasome activation.
Myeloid Abca1/g1 Deficiency Activates the NLRP3 Inflammasome by Inducing the Noncanonical Inflammasome
Noncanonical inflammasome activation induces caspase-11 cleavage, leading to activation of the NLRP3 inflammasome. 32 We found that myeloid Abca1/g1 deficiency enhanced caspase-11 cleavage in splenic CD11b + cells moderately on the chow diet (Figure XA in the online-only Data Supplement) 15 and markedly in Ldlr -/-mice fed WTD. Consistent with previous studies of the noncanonical inflammasome, 32 this was independent of Nlrp3 ( Figure 6A and 6B) . Abca1/g1 deficiency enhanced caspase-11 cleavage in Ly6G + neutrophils and Ly6G Continued. K and L, Lysotracker staining was assessed using flow cytometry in CD11b + monocytes, F4/80 + macrophages, and CD11b int neutrophils, gated as in Figure VIIIA in the online-only Data Supplement. M, Mice were fed WTD for 1 week and injected with reconstituted high-density lipoprotein (rHDL; CSL-111; 120 mg/kg), and the increase in plasma IL-18 levels was assessed at 1 week after injection (n=7 mice per group; each data point represents 1 mouse). N, ATP secretion from total splenic CD115 + monocytes was assessed by using luciferase assay, n=6 (A, C, E, F, H, J, L, N) or n=7 (M) mice per group. *P<0.05, **P<0.01, ***P<0.001 by t test (A, C, E, F, H, J, L, N) , or 1-way ANOVA with Bonferroni posttest (M). ABC indicates ATP binding cassette; AU, arbitrary units; BM, bone marrow; casp, caspase; chol, cholesterol; ctrl, control; DAPI, 4ʹ,6-diamidino-2-phenylindole; IL, interleukin; mfi, mean fluorescent intensity; and WTD, Western-type diet.
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tic shock). 32 To substantiate our findings that myeloid Abca1/g1 deficiency activates the noncanonical inflammasome pathway, we performed a lipopolysaccharide mortality study. We used a chow diet to reduce variability in response, which nonetheless is associated with a moderate level of lipid accumulation in monocytes/ macrophages, 15 
DISCUSSION
Our findings indicate that cholesterol accumulation in Abca1/g1-deficient myeloid cells activates the NLRP3 inflammasome promoting neutrophil infiltration and NETosis in atherosclerotic lesions. In contrast to the current view of a cholesterol crystal-stimulated activation of the macrophage inflammasome within atherosclerotic lesions, 4 our findings suggest a systemic effect of myeloid inflammasome activation indirectly stimulating neutrophil activation and entry in plaques, leading to prominent NETosis. Moreover, inflammasome activation appears to involve both increased levels of NLRP3 inflammasome components, likely a Toll-like receptor 4-mediated priming effect, and a membrane cholesterol-sensing mechanism that leads to noncanonical inflammasome activation upstream of the NLRP3 inflammasome and increases susceptibility to lipopolysaccharide-induced death.
NETosis has been shown to promote atherosclerotic plaque development in mice, 33, 34 and has been associated with features of plaque instability or erosion in humans. 24, [35] [36] [37] Mouse studies have indicated a role of NETosis in the development of advanced atherosclerotic lesions 33, 34 and have shown that NETosis can promote macrophage inflammasome activation. 34 In contrast, our studies show prominent neutrophil accumulation and NETosis in early but not late atherosclerotic lesions, consistent with a significant body of literature indicating a role for neutrophils in early atherogenesis. 22, 23, 38 Moreover, in our model, abolition of lesional neutrophil accumulation and NETosis by Caspase-1/11 or Nlrp3 deficiency shows for the first time that neutrophil recruitment and NETosis can be induced downstream of inflammasome activation. A potential explanation for these findings would be that neutrophil cholesterol accumulation in mice with myeloid Abca1/g1 deficiency led to inflammasome activation, which in turn promoted NETosis as a mode of neutrophil death. However, several observations suggest that NETosis may not be due to a cell-intrinsic effect in neutrophils. Myeloid Abca1/g1 deficiency did not enhance caspase-1 or caspase-11 cleavage in neutrophils of atherosclerotic plaques or spontaneous NETosis in isolated blood neutrophils. NETosis may thus be due to enhanced neutrophil recruitment or activation as a systemic consequence of inflammasome activation in myeloid cells rather than a cell-intrinsic effect in neutrophils. NLRP3 inflammasome slightly enhanced neutrophilia in myeloid Abca1/g1-deficient Ldlr -/-mice, consistent with NLRP3 inflammasome-dependent IL-1β secretion. IL-1β may also promote binding and entry of myeloid cells into plaques. 6, 39 Our findings are thus more consistent with systemic effects of NLRP3 inflammasome activation than local effects in atherosclerotic lesions.
Earlier studies have emphasized the role of cholesterol crystals in inflammasome activation and NETosis. 34 However, our studies in Abca1/g1-deficient macrophages point to a role of endosomal and membrane cholesterol accumulation without obvious cholesterol crystal formation or lysosomal damage. Moreover, in vivo the major effects of the inflammasome were seen in early lesions when cholesterol crystals are not readily observed. In contrast to the predictions of phase diagrams based on the lipid composition of macrophage foam cell predominant atherosclerotic lesions, 40 confocal reflectance microscopy studies have suggested abundant cholesterol crystals in early mouse atherosclerotic plaques. 4 However, some of this crystalline material may have been formed during sample processing because of the ready crystallization of cholesteryl esters in refrigerated samples.
In contrast to some previous studies, 4,9-12 we found no effect of hematopoietic Nlrp3 or Caspase-1/11 deficiency on atherogenesis in Ldlr -/-mice. Based on our data in Ldlr -/-mice showing that hematopoietic Nlrp3 deficiency did not reduce plasma IL-18 levels, whereas Caspase-1/11 deficiency had only a small effect, we attribute these findings to a lack of NLRP3 inflammasome activation. Studies showing that the NLRP3 inflammasome only contributed to atherogenesis in the setting of enhanced activation because of mitochondrial ROS accumulation or the TET2 mutation, but not in the control Ldlr -/-condition, 3, 14 support this interpretation. Several NLRP3 inflammasome components also did not affect atherogenesis in Apoe -/-mice fed a diet containing 1.25% cholesterol. 13 Although the lack of an effect has been attributed to the high cholesterol content of the diet, 41 the absence of inflammasome activation in Apoe -/-mice or differences in the microbiome could also explain these results. The microbiome from Nlrp3 -/-and Nlrp6 -/-mice has been reported to enhance inflammation via myeloid differentiation primary response 88 and toll interleukin-1 receptor (TIR)-domain-containing adapter-inducing interferon-β (TRIF) pathways, 42 which could produce variable effects and complicate the interpretation of atherosclerosis results in compound knockout mice.
We found increased inflammasome priming in Abca1/g1-deficient splenic monocytes, macrophages, and neutrophils, which likely contributed to NLRP3 inflammasome activation. Excessive membrane cholesterol content in Abca1/g1-deficient macrophages enhanced the interaction between Toll-like receptor 4 and MD-2, stimulating Toll-like receptor 4-induced gene expression. 31 It is interesting to note that cholesterol may interact with phospholipids in membranes
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to propagate inflammatory signals induced by lipopolysaccharide, 43 consistent with excessive membrane cholesterol accumulation enhancing inflammasome priming, as we observed. Enhanced cholesterol synthesis in cells deficient in cholesterol-25-hydroxylase has been associated with activation of the AIM-2 inflammasome because of mitochondrial damage enhancing mitochondrial DNA release into the cytosol. 44 Mitochondrial damage was also associated with accumulation of mitochondrial ROS, 44 which activates the NLRP3 inflammasome. 28 We did not observe enhanced mitochondrial ROS accumulation in our myeloid Abca1/g1-deficient model, suggesting a distinct activation mechanism. In sum, these findings suggest that cholesterol accumulation in myeloid cells can activate the inflammasome via several pathways, including inflammasome priming, mitochondrial damage, and caspase-11 cleavage.
Our study points to a major role of the noncanonical inflammasome initiated by caspase-11 cleavage acting upstream of the NLRP3 inflammasome in monocytes, macrophages, and neutrophils. Although cytosolic lipopolysaccharide accumulation has been implicated as an activation mechanism of the noncanonical inflammasome, 32 upstream signals and sensors relevant to metabolic disease are uncertain 45 and could be related to excessive membrane cholesterol content. Our findings suggest that noncanonical inflammasome activation contributes to NLRP3 inflammasome activation and atherogenesis in Myl-Abc dko BMT Ldlr -/-mice fed WTD and to sepsis in Myl-Abc dko mice on chow diet. The elevated levels of plasma IL-1β and IL-18 in patients with TD suggest that myeloid cholesterol accumulation may also contribute to inflammasome activation in humans. Patients with TD sometimes present with premature atherosclerotic cardiovascular disease, 46 but the more consistent phenotype among adult patients with TD is peripheral neuropathy. 25 A recent study has shown that defective myelin clearance due to macrophage Abca1/g1 deficiency promotes inflammasome activation and limits remyelination in the central nervous system in aged mice. 47 Together with our findings, this suggests that macrophage inflammasome activation may be involved in the pathogenesis of peripheral neuropathy in TD. Patients with TD could also be susceptible to a sepsis-induced hyperinflammatory state due to inflammasome activation. Although TD is rare, low levels of ABCA1/G1 in monocyte/macrophages along with low HDL levels may commonly occur in humans with poorly controlled diabetes mellitus, 48 with chronic kidney disease, 49 or simply with ageing. 47 Targeting the NLRP3 or noncanonical inflammasome, or their products, in susceptible patients represents an attractive area for future atherosclerosis research.
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